newsfilter
← Latest News
Business Wire·

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipeline Multiple